NASDAQ · TGTXHealthcarePharmaceuticals

TG Therapeutics news

$56.190.00%
Close Sep 29, 2026 · split-adjusted
Articles · 30 days1English, de-duplicated
Positive00% of coverage
Neutral1100%
Negative00% of coverage

About TG Therapeutics

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
Zacks Investment ResearchSep 2, 11:30 AM ETNeutral

Mixed signals: strong revenue growth (+70.3% YoY) and raised guidance are positive, but EPS miss ($0.05 vs. $0.41), downward estimate revisions post-earnings, and poor VGM scores (F for Growth and Momentum, D for Value) suggest limited near-term upside. Zacks Rank #3 (Hold) indicates in-line returns expected.

Also mentions TGTX

Articles that tag TGTX but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology